Taming the Medical Literature ~ For Genetic Conditions ~ Hand-Curated • Direct to You
LitAlert ~~ GeneLit.com
Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Coquard I.
J Natl Cancer Inst. 2020 Dec 29. pii: djaa193. doi: 10.1093/jnci/djaa193. [Epub ahead of print]
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
Ryan K, Bolaños B, Smith M, Palde P, Cuenca PD, VanArsdale TL, Niessen S, Zhang L, Behenna D, Ornelas MA, Tran KT, Kaiser S, Lum L, Stewart A, Gajiwala KS.
J Biol Chem. 2020 Dec 24:jbc.RA120.016573. doi: 10.1074/jbc.RA120.016573. Epub ahead of print.
Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q.
Cancer Manag Res. 2020 Dec 16;12:12919-12926. doi: 10.2147/CMAR.S283169.
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.
Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R.
World J Gastrointest Oncol. 2020 Dec 15;12(12):1456-1463. doi: 10.4251/wjgo.v12.i12.1456.